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ABSTRACT
Objectives: Inguinal lymphadenectomy used in the treatment of vulvar cancer often results in complications, such as 
lymphoedema or abnormal wound healing. Aim of this study was assessment of the diagnostic effectiveness of the sentinel 
lymph node biopsy (SLNB) procedure in patients treated due to vulvar cancer. 
Material and methods: Eighty-four patients diagnosed with squamous cell vulvar carcinoma (FIGO I-IV) underwent 
preoperative lymphoscintigraphy with technetium 99 to map sentinel lymph node. During surgery sentinel lymph nodes 
were identified and resected, followed by complete bilateral groin lymphadenectomy.
Results: Sentinel lymph nodes were mapped with lymphoscintigraphy and biopsied in 84.3% and 90.1% of patients, respec-
tively. False negative predictive value (FNPV) was 9.1% and false negative rate (FNR) was recorded in 16.7% of cases. Patients 
in advanced stages (FIGO III and IV) had significantly lower rate of lymphatic mapping compared to those in stage I and II 
(OR = 0.148, p = 0.022). Detection of sentinel lymph node in lymphoscintigraphy for tumor grade 2 and 3 was nearly eight 
times lower than for grade 1 cancers, however without statistical significance (OR = 0.126, p = 0.058). 
Conclusions: The use of SLNB should be limited to vulvar cancer patients in early clinical stages.
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INTRODUCTION
Vulvar cancer accounts for about 5% of all female ge-
nital cancers [1]. In 2016, 490 new cases of vulvar cancer 
were diagnosed in Poland [2]. Lymph nodes involvement 
is considered as the most important prognostic factor in 
vulvar cancer [3]. 
Nowadays, sentinel lymph node biopsy (SLNB) is the 
standard procedure for surgical assessment of melanoma, 
breast cancer, penile cancer and female genital cancers, 
including vulvar cancer. Lymphoscintigraphy requires 
standardization for appropriate sentinel lymph nodes 
mapping. Intraoperative identification of sentinel node 
and histopathological examination are subsequent crucial 
steps in SLNB. 
Implementing sentinel lymph node procedure in clini-
cal practice requires systematic validation. The purpose of 
this study was a retrospective assessment of the diagnostic 
effectiveness of the SLNB in the first 7-year period after 
implementation this method into clinical practice in our 
department. 
MATERIAL AND METHODS
The analysis included patients with vulvar cancer 
who were treated between 2001 and 2007. Patients were 
staged according to the FIGO 1994 classification. Dur-
ing this period 115 women were treated at the Depart-
ment. 17 cases of stage III were treated with radio(chemo)
therapy exclusively, 7 patients of stage IV underwent 
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chemotherapy based on cisplatin and 5-fluorouracil, 3 pa-
tients were disqualified from treatment due to advanced 
disease and poor general condition. In 4 cases vulvar 
melanoma was diagnosed — all of these patients were 
not included in the analysis. Patients with histopatho-
logical diagnosis of vulvar squamous cell carcinoma only 
were eligible for the study. Finally, the analysis included 
a total of 84 patients. 
The sentinel lymph node biopsy procedure was per-
formed in all 84 patients. It consisted of preoperative lym-
phoscintigraphy, intraoperative detection and biopsy of 
a radioisotope identified sentinel node, and finally histo-
pathological evaluation.
The SLNB procedure was performed according to the 
two-day (long) protocol: radioisotope was administered 
16–20 hours before surgery. Preoperative lymphoscintig-
raphy with nano-colloid radiolabelled technetium isotope 
(99mTc) was used. The radioactive marker was administered 
subcutaneously in four injections around the tumor, at a dose 
of 74 MBq (18.5 MBq × 4). Lymphoscintigraphy imaging 
was performed with planar technique after 2 hours, using 
a two-head gamma camera with a low-energy collimator, on 
the sensor 128 × 128. The energy window was adapted to 
the energy of the 99mTc isotope radiation (140 keV) that was 
used in the procedure. The data obtained was developed 
using dedicated workstations. The result of the radioisotope 
examination was transmitted to the operating team. During 
the surgery, lymph node with the largest isotope uptake in 
the groins was identified with manual gamma camera. The 
lymph node was considered as sentinel if isotopic activity in 
the wound decreased at least three times after its removal. 
Then a bilateral inguinal lymphadenectomy was performed. 
In cases with the lack of sentinel node localization, a com-
plete groin lymphadenectomy was performed. Lymph nodes 
considered as sentinel were sent separately for histopatho-
logical examination. This evaluation was carried out with 
immunohistochemical staining with cytokeratin 7 and 19.
Sentinel lymph node was considered as involved if me-
tastasis was found. 
Non-sentinel lymph nodes were considered as to be 
involved if metastasis was found in at least 1 non-sentinel 
lymph node. 
The medium percentage of lymph nodes detected dur-
ing the surgery as well as sensitivity, specificity, positive 
and negative predictive values (PPV, NPV) were estimated. 
The estimates are given along with 95% confidence inter-
vals. Factors that could possibly affect the detection of sen-
tinel node were also examined. For this purpose, the logistic 
regression model was used. Grading (G), clinical stage, age, 
the largest dimension and localization of the tumor were 
included in this model. To optimize the analysis, continuous 
variables have been categorized.
Effectiveness of sentinel lymph node identification in 
lymphoscintigraphy was assessed and potential factors 
that could affect it were examined. Compatibility of lym-
phoscintigraphic and surgical sentinel nodes detection was 
estimated.
All hypotheses were tested at a level of statistical sig-
nificance of 0.05.
Standard descriptive statistics tools are used to describe 
the study material. The statistical analysis was carried out 
with the IBM SPSS Statistics 23 statistical package. Due to 
the retrospective character of the study, the consent of the 
bioethics committee was not required.
RESULTS
The study group consisted of 84 women. Mean age was 
66 years old (18 to 94, standard deviation: 14). The largest 
dimension of the tumor ranged from 5 to 90 mm (median: 
35 mm), interquartile range (IQR): 22–50. Characteristics of 
study group was presented in Table 1.
Surgical and pathological evaluation of SLNB
Sentinel lymph node was found in 90.1% of patients. The 
estimated sensitivity and specificity were 54.5% (25.1– 
–83.9%), and 83.3% (73.9–92.7%), respectively. The positive 
Table 1. Clinical characteristics of study group.
Number  
of patients
Percentage 
of patients
FIGO (1994)
IA 1 1.2
IB 11 13.1
II 35 41.7
III 31 36.9
IV 6 7.1
Grading
1 29 36.7
2 37 48.1
3 12 15.2
missing 6
Side
right 27 41.8
left 13 20.9
midline 44 37.3
Multifocal
no 79 94.1
yes 5 5.9
Age [years] 
< 62 26 31.0
62–73 30 35.7
> 73 28 33.3
Maximum tumor size [mm]
≤ 25 31 37.3
25–45 22 26.5
≥ 45 30 36.1
missing 1
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and negative predictive values (PPV and NPV) were 37.5% 
(13.8–61.2%) and 90.9% (83.3–98.5%), respectively. False 
negative predictive value (FNPV) was recorded in 9.1% of 
patients and false negative rate (FNR) was found in 16.7% 
of patients. Detailed statistical analysis was presented in 
Table 2. All analysed factors (i.e. age, maximum tumor size, 
staging, grading) were not significant for intraoperative 
sentinel lymph node detection (p > 0.1).
Lymphoscintigraphy assessment
Lymphoscintigraphy revealed sentinel lymph node in 
84.3% (76.5–92.1%) of patients. Patients with FIGO stage 
I and II were almost 7 times more likely to find sentinel lymph 
nodes with 99mTc scintigraphy then those with stage III and 
IV (OR = 0.148, p = 0.022). Correlation between histological 
grading and lymphoscintigraphy was close to the statistical 
significance level (p = 0.058). Chance for sentinel lymph 
node detection in tumors G2 and G3 compared to G1 was 
almost eight times lower (OR = 0.126). Logistic model ana-
lysis was presented in Table 3.
Comparison of lymphoscintigraphy and surgery
There was no correlation between lymphoscintigraphy 
outcome and surgical evaluation of sentinel lymph node 
site. The estimated values of kappa coefficient for the left 
and right side were 0.192 (p = 0.0638) and 0.048 (p = 0.628), 
respectively.
DISCUSSION
The status of regional lymph nodes is the most essential 
of all known risk factors for vulvar cancer recurrence [4]. The 
assessment of lymphatic drainage in vulvar cancer is impor-
tant, especially in fact that in clinical stage I and II metastases 
to regional nodes occur at 10.7%, 26.2%, respectively [5]. In 
the past, surgical treatment of the vulvar cancer relied on en 
bloc resection of the vulva and inguinal lymph nodes. Post-
operative period after such disabling surgeries was compli-
cated by long wound healing, infections and psychologi-
cal problems. In the 1970s, surgical management of vulvar 
cancer resection was modified to triple incision technic. It 
has improved postoperative period significantly, especially 
wound healing and reducing long hospitalization stay.
In mid 1990s, SLNB was introduced in vulvar cancer [6, 7]. 
Lymphoscintigraphy with 99mTc was the most regularly used 
technique with high accuracy of mapping lymphatic draina-
ge [8–10]. Therefore since 2000, we used this method in our 
Department to perform SLNB in patients with vulvar cancer. 
The study analysed data covering the period between 
2001 and 2007; the eligibility criteria for SLNB in vulvar cancer 
patients were not established. At that time in our department, 
all patients with malignant vulvar neoplasms were qualified 
to SLNB, regardless of tumor size (in 32 patients tumor size 
was > 4 cm, and the largest tumor dimension was 90 mm), 
abnormal inguinal lymph in physical examination and imaging. 
90.1% of patients had at least one sentinel lymph node found 
Table 2. The sensitivity1, specificity2, PPV3, NPV4, FNPV5, FNR6 of SLNB in 71 patients. All 84 patients underwent SLNB but in 13 women pathological 
results were imprecise. Therefore, these patients were not included in the analysis. In these cases, the histopathological report: (1) did not specify 
which lymph nodes were sentinel; (2) contained the total number of resected and metastatic lymph nodes without taking into consideration 
site of lymphadenectomy
Non-sentinel lymph node
Total
Negative Positive
Sentinel lymph nodes
Negative
N 50 5 55
% within SLN 90.9%4 9.1%5 100%
% within non-SLN 83.3%2 45.5% 77.5%
Positive
N 10 6 16
% within SLN 62.5% 37.5%3 100%
% within non-SLN 16.7%6 54.5%1 22.5%
Total
N 60 11 71
% within SLN 84.5% 15.5% 100%
% within non-SLN 100% 100% 100%
Table 3. The parameters of the final logistic model for chance of lymph nodes detection in scintigraphy
Beta coefficient SE of Beta p OR 95%-confidence interval
Stage G > 1 –2.071 1.093 0.058 0.126 0.015 1.075
Clinical stage (1994) > 2 –1.911 0.832 0.022 0.148 0.029 0.755
Constant 4.527 1.230 < 0.001 92.2
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during operation. This result may be disappointing regard-
ing study of Vidal-Sicart et al. [11], who found sentinel lymph 
nodes in 98% of patients. However, our results are acceptable 
regarding that SLNB has just been introduced as a new technic 
in those days and wide eligibility criteria for the procedure. 
Learning curve in SLNB as well as developing lymphoscintig-
raphy technique certainly had an impact on such result [12]. 
None of analysed factors (grading, staging, age, the maxi-
mum dimension and localization of the tumor) were relevant 
in intraoperative sentinel lymph node detection. However, in 
the meta-analysis, Hassanzade et al. [13] showed that efficacy 
of sentinel lymph node identification depended on the maxi-
mum tumor size and was 7% higher in tumors less than 4 cm. 
The total efficacy of sentinel lymph node detection was 94.4% 
(regarding to patient) and 84.6% (regarding to a groin) [13]. 
Currently, the most regularly used criteria (ESGO and 
NCCN recommendations) for sentinel lymph nodes detect-
ing include: 1) tumors less than 4 cm, 2) clinically not en-
larged groin lymph nodes and 3) lack of abnormal imaging 
[14, 15]. Nowadays, according to these criteria, only selected 
patients are qualified to SLNB in our department. The recom-
mendations are the results of the clinical trial — GROINSS V 
[16]. Patients suffering from squamous vulvar cancer with 
a maximum tumor diameter < 4 cm were qualified to this 
study. False negative predictive value was 2.9% in the trial. 
In our analysis, FNPV was 3 times higher and reached 9.1 %. 
Probably, this was due to the qualification of patients regard-
less of tumor size — 36.1% of patients had tumors > 4.5 cm 
in diameter. It may be caused by complete blockage of lym-
phatic vessels by cancer cells in large tumors [13]. Results of 
the GOG 173 study confirmed this thesis — FNPV for tumors 
4–6 cm was 7.4%, while in tumors < 4 cm decreased to 2% 
[17]. In this prospective study FNR was 8.3%, compared to 
16.7 % presented in our paper. That is an argument for quali-
fying patients with tumors up to 4 cm for the procedure of 
sentinel node detection. According to Levenback et al. [17] 
FNR can be reduced by using radiocolloid and dye. 
We found that staging (p = 0.022) and tumor grading 
(p = 0.058) may be related to efficacy of the lymphoscintig-
raphy. In the literature, no analysis has been found regarding 
clinicopathological factors and the lymphoscintigraphy results.
The study was a retrospective analysis and had some 
limitations. Staging of vulvar cancer was conducted accor-
ding to FIGO classification from 1994. Another problem 
was related to definition of SLNB. A sentinel lymph node 
identified by gamma probe have radioactivity at least ten 
times higher than the background counts. This definition 
comes from practice guideline in gynecological cancers of 
The European Association of Nuclear Medicine published in 
2014 [18]. In our study, covering the years 2001-2007, radio-
activity at least three times the background was adopted to 
mark the node as SLN. This could affect the results. 
CONCLUSIONS
These results became starting point for improving SLNB 
in clinical practice and conducting further research in this 
area. In our opinion, SLNB should be limited to patients with 
vulvar cancer in early clinical stages.
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